RT Journal Article
SR Electronic
T1 A new multi-species Protein A-ELISA assay for plague diagnosis in humans and other mammal hosts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.21.21263536
DO 10.1101/2021.09.21.21263536
A1 Bezerra, Matheus Filgueira
A1 Xavier, Camila Cavalcanti
A1 de Almeida, Alzira Maria Paiva
A1 de Souza Reis, Christian Robson
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263536.abstract
AB Background The Hemagglutination assay (HA) is widely used in plague diagnosis, however, it has a subjective interpretation and demands high amounts of antigen and other immunobiological supplies. Conventional IgG-ELISA is limited by the need of specific conjugates for multiple plague hosts.Methods Thus, we developed an ELISA Protein A-peroxidase method to detect anti-F1 antibodies across several species, including humans. To determine the cut-off and performance rates, HA results from 288 samples (81 rabbits, 64 humans, 66 rodents and 77 dogs) were used as reference.Results Optimal conditions were found with 250ng/well of F1 and 1:500 serum dilution. Protein A-ELISA showed high repeatability and reproducibility. The positive/negative OD ratios were higher in Protein A-ELISA and there was no significant cross-reaction with other pathogenic yersiniae. The overall sensitivity/specificity, area under the curve and Kappa rates for Protein A-ELISA were 93.9/98.9%; 0.993 and 0.938, respectively. Similar results were observed in each species separately. There was a strong agreement between Protein A and IgG assays (kappa=0.973) in independent analysis (n=487).Conclusions Altogether, the Protein A-ELISA showed high performance when compared both to HA and IgG-ELISA, with a polyvalent single protocol that requires reduced amounts of antigen and can be employed to any plague hosts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq grant 422612/20162).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The production of immune sera for positive controls in rabbits is routinely produced following the local Animal Ethics Committees (CEUA-Fiocruz) standards and was approved with the protocol number L-020/09, Comissao de Etica no Uso de Animais - Fiocruz. The use of human sera samples in the research was approved by the Aggeu Magalhaes Institute Ethics Committee (protocol number CAAE 50163615.8.0000.5190).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther details on the dataset can be provided by authors upon request.